These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 23143747)

  • 1. TRAIL suppresses tumor growth in mice by inducing tumor-infiltrating CD4(+)CD25 (+) Treg apoptosis.
    Diao Z; Shi J; Zhu J; Yuan H; Ru Q; Liu S; Liu Y; Zheng D
    Cancer Immunol Immunother; 2013 Apr; 62(4):653-63. PubMed ID: 23143747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Changes of regulatory T cell number in hepatocellular carcinoma-bearing mice and its relationship with tumor growth].
    Zhang P; Zhang LN; Zhu FL; Wang Q; Wang XY; Li HY; Liu CM; Gao F; Liu CH
    Zhonghua Zhong Liu Za Zhi; 2007 May; 29(5):342-5. PubMed ID: 17892128
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor necrosis factor-related apoptosis-inducing ligand inhibits experimental autoimmune thyroiditis by the expansion of CD4+CD25+ regulatory T cells.
    Wang SH; Chen GH; Fan Y; Van Antwerp M; Baker JR
    Endocrinology; 2009 Apr; 150(4):2000-7. PubMed ID: 19008314
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blockade of TGF-β signaling to enhance the antitumor response is accompanied by dysregulation of the functional activity of CD4
    Polanczyk MJ; Walker E; Haley D; Guerrouahen BS; Akporiaye ET
    J Transl Med; 2019 Jul; 17(1):219. PubMed ID: 31288845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunosuppressive drugs on inducing Ag-specific CD4(+)CD25(+)Foxp3(+) Treg cells during immune response in vivo.
    Wu T; Zhang L; Xu K; Sun C; Lei T; Peng J; Liu G; Wang R; Zhao Y
    Transpl Immunol; 2012 Aug; 27(1):30-8. PubMed ID: 22613676
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD4+CD25+ Treg derived from hepatocellular carcinoma mice inhibits tumor immunity.
    Chen X; Du Y; Huang Z
    Immunol Lett; 2012; 148(1):83-9. PubMed ID: 23000301
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Involvement of cellular death in TRAIL/DR5-dependent suppression induced by CD4(+)CD25(+) regulatory T cells.
    Ren X; Ye F; Jiang Z; Chu Y; Xiong S; Wang Y
    Cell Death Differ; 2007 Dec; 14(12):2076-84. PubMed ID: 17762882
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulatory T cells express Tumor Necrosis Factor Receptor 2 with the highest intensity among CD4
    Ghods A; Mehdipour F; Shariat M; Talei AR; Ghaderi A
    Mol Immunol; 2021 Sep; 137():52-56. PubMed ID: 34214829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of SLC administration and Tregs depletion is an attractive strategy for targeting hepatocellular carcinoma.
    Chen L; Zhou S; Qin J; Hu H; Ma H; Liu B; Wang X; Ma J; Ye S; Zhong C; Zhou G; Liang C
    Mol Cancer; 2013 Dec; 12(1):153. PubMed ID: 24304581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual effects of TRAIL in suppression of autoimmunity: the inhibition of Th1 cells and the promotion of regulatory T cells.
    Ikeda T; Hirata S; Fukushima S; Matsunaga Y; Ito T; Uchino M; Nishimura Y; Senju S
    J Immunol; 2010 Nov; 185(9):5259-67. PubMed ID: 20921531
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD4+CD25+ Tregs control the TRAIL-dependent cytotoxicity of tumor-infiltrating DCs in rodent models of colon cancer.
    Roux S; Apetoh L; Chalmin F; Ladoire S; Mignot G; Puig PE; Lauvau G; Zitvogel L; Martin F; Chauffert B; Yagita H; Solary E; Ghiringhelli F
    J Clin Invest; 2008 Nov; 118(11):3751-61. PubMed ID: 18830416
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased CD4+CD25+Foxp3+ regulatory T cells in tolerance induced by portal venous injection.
    He F; Chen Z; Xu S; Cai M; Wu M; Li H; Chen X
    Surgery; 2009 Jun; 145(6):663-74. PubMed ID: 19486771
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor-infiltrating CD4+ T lymphocytes express APO2 ligand (APO2L)/TRAIL upon specific stimulation with autologous lung carcinoma cells: role of IFN-alpha on APO2L/TRAIL expression and -mediated cytotoxicity.
    Dorothée G; Vergnon I; Menez J; Echchakir H; Grunenwald D; Kubin M; Chouaib S; Mami-Chouaib F
    J Immunol; 2002 Jul; 169(2):809-17. PubMed ID: 12097384
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative analyses of regulatory T cell subsets in patients with hepatocellular carcinoma: a crucial role of CD25(-) FOXP3(-) T cells.
    Kakita N; Kanto T; Itose I; Kuroda S; Inoue M; Matsubara T; Higashitani K; Miyazaki M; Sakakibara M; Hiramatsu N; Takehara T; Kasahara A; Hayashi N
    Int J Cancer; 2012 Dec; 131(11):2573-83. PubMed ID: 22419479
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Depletion of CD4(+)CD25(+) regulatory T cells can promote local immunity to suppress tumor growth in benzo[a]pyrene-induced forestomach carcinoma.
    Chen YL; Fang JH; Lai MD; Shan YS
    World J Gastroenterol; 2008 Oct; 14(38):5797-809. PubMed ID: 18855977
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The ratios of CD8+ T cells to CD4+CD25+ FOXP3+ and FOXP3- T cells correlate with poor clinical outcome in human serous ovarian cancer.
    Preston CC; Maurer MJ; Oberg AL; Visscher DW; Kalli KR; Hartmann LC; Goode EL; Knutson KL
    PLoS One; 2013; 8(11):e80063. PubMed ID: 24244610
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sorafenib relieves cell-intrinsic and cell-extrinsic inhibitions of effector T cells in tumor microenvironment to augment antitumor immunity.
    Chen ML; Yan BS; Lu WC; Chen MH; Yu SL; Yang PC; Cheng AL
    Int J Cancer; 2014 Jan; 134(2):319-31. PubMed ID: 23818246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-dose splenic radiation inhibits liver tumor development of rats through functional changes in CD4+CD25+Treg cells.
    Wang B; Li B; Dai Z; Ren S; Bai M; Wang Z; Li Z; Lin S; Wang Z; Huang N; Yang P; Liu M; Min W; Ma H
    Int J Biochem Cell Biol; 2014 Oct; 55():98-108. PubMed ID: 25168696
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Requirement of cognate CD4+ T-cell recognition for the regulation of allospecific CTL by human CD4+ CD127- CD25+ FOXP3+ cells generated in MLR.
    Yu Y; Miller J; Leventhal JR; Tambur AR; Chandrasekaran D; Levitsky J; Luo X; Mathew JM
    PLoS One; 2011; 6(7):e22450. PubMed ID: 21799858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Methyl gallate exhibits potent antitumor activities by inhibiting tumor infiltration of CD4+CD25+ regulatory T cells.
    Lee H; Lee H; Kwon Y; Lee JH; Kim J; Shin MK; Kim SH; Bae H
    J Immunol; 2010 Dec; 185(11):6698-705. PubMed ID: 21048105
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.